This content is machine translated ASCO 2018 in Chicago Study news on lung, kidney and intestine KEYNOTE-042 and CARMENA: Two studies that have the potential to change practice. It’s about lung cancer – as so often lately – but also about renal cell carcinoma. Furthermore, the…
View Post 7 min This content is machine translated Advanced training course in clinical oncology in St. Gallen Metastatic colorectal cancer “beyond surgery”. At the advanced training course in clinical oncology in St. Gallen, there was also a symposium on colorectal carcinoma, among other topics. In an overview, Prof. Dr. med. Ralf-Dieter Hofheinz,…
View Post 4 min This content is machine translated World Congress of Dermatology Scalp and hair in focus The 23rd World Congress of Dermatology was held in Vancouver in June. In addition to the large, prominently placed studies, various smaller studies were also convincing with their interesting approaches…
View Post 4 min This content is machine translated Metastatic colorectal cancer Comparison between bevacizumab and cetuximab in KRAS exon2 wild type. According to preliminary results of a large phase III trial presented at this year’s ASCO congress, bevacizumab and cetuximab (combined with FOLFOX or FOLFIRI) show similar efficacy in terms of…
View Post 6 min This content is machine translated Interview at ASCO GI on new data from the OPUS study. “We are a good step closer to personalized therapy in mCRC” In the treatment of metastatic colorectal cancer, there were new results on subgroup analyses of the OPUS trial at this year’s ASCO GI in San Francisco. As previously shown in…
View Post 4 min This content is machine translated 1st Swiss Symposium Peritoneal Malignancies and HIPEC Enabling individualized treatment At the first Swiss symposium on peritoneal malignancies and HIPEC in St. Gallen, experts spoke on the topics of ovarian cancer and metastatic colorectal cancer. It was about current and…
View Post 4 min This content is machine translated Treatment of metastatic colorectal carcinoma. Patients with RAS wild type benefit in overall survival New data on first-line treatment of metastatic colorectal cancer were presented at the ASCO GI in San Francisco. The post-hoc analyses consistently confirm that RAS mutation status is an important…
